Shinya Sutani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinya Sutani has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Atsunori Yorozu
Department of Radiology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
2 shared publicationsKazuhito Toya
Department of Radiology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan; Department of Radiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan
2 shared publicationsKen Nakamura
Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
2 shared publicationsShiro Saito
Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
2 shared publicationsToru Nishiyama
Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
2 shared publicationsYasuto Yagi
Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
2 shared publications
Latest Publications
- 1 January 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (1) , 10-18
Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score–matched analysis
- 1 January 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (1) , 10-18
Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score–matched analysis
- Open Access
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 11 (3) , 201-206
Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of 125I brachytherapy and robot-assisted radical prostatectomy
Purpose To analyze outcomes following whole-gland salvage treatments applied to patients with pathology-proven, locally recurrent prostate cancer following primary definitive radiotherapy. Material and methods Eighteen consecutive patients who received whole-gland salvage treatments at our...
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 11 (3) , 201-206
Open AccessWhole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of 125I brachytherapy and robot-assisted radical prostatectomy
Purpose To analyze outcomes following whole-gland salvage treatments applied to patients with pathology-proven, locally recurrent prostate cancer following primary definitive radiotherapy. Material and methods Eighteen consecutive patients who received whole-gland salvage treatments at our...
- Open Access
- 12 October 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 208
Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes
We report the feasibility and treatment outcomes of image-guided three-dimensional conformal arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer. Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78–86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade 2–3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late grade 4 or higher toxicity. In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment outcomes were comparable to those previously reported for intensity-modulated radiotherapy.
- 12 October 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 208
Open AccessThree-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes
We report the feasibility and treatment outcomes of image-guided three-dimensional conformal arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer. Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78–86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade 2–3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late grade 4 or higher toxicity. In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment outcomes were comparable to those previously reported for intensity-modulated radiotherapy.